Cat. No.: HY-B0738

Dithranol

(Synonyms: Anthralin)

Customer Review

Based on 1 Customer Validation

Dithranol (Anthralin) is an anthraquinone derivative, with potent anti-psoriatic effects. Dithranol can inhibit DNA replication and repair.

For research use only. We do not sell to patients.

Purity: 95.26%
CAS No.: 1143-38-0
Formula: C₁₄H₁₀O₃
Molecular Weight:226.23

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Dithranol Chemical Structure

CAS No.: 1143-38-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Dithranol (Anthralin) is an anthraquinone derivative, with potent anti-psoriatic effects. Dithranol can inhibit DNA replication and repair^[1]^[2].

All DNA/RNA Synthesis Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HaCaT	GI₅₀	0.7 μM Compound: 14	Growth inhibition of human HaCaT cells after 72 hrs by neutral red uptake assay Growth inhibition of human HaCaT cells after 72 hrs by neutral red uptake assay	[PMID: 22944332]
HaCaT	IC₅₀	0.2 μM Compound: anthralin	Antiproliferative activity against HaCaT cells Antiproliferative activity against HaCaT cells	[PMID: 8201600]
HaCaT	IC₅₀	0.6 μM Compound: 1/ Anthralin	Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line) Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)	[PMID: 9371243]
HaCaT	IC₅₀	0.6 μM Compound: anthralin	Antiproliferative activity (AA) against HaCaT keratinocytes. Antiproliferative activity (AA) against HaCaT keratinocytes.	[PMID: 9276024]
HaCaT	IC₅₀	0.7 μM Compound: 1	Antiproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy Antiproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy	[PMID: 20452101]
HaCaT	IC₅₀	0.7 μM Compound: 1	Antiproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy Antiproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy	[PMID: 20828887]
HaCaT	IC₅₀	0.7 μM Compound: 2	Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopic analysis Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopic analysis	[PMID: 26840368]
HaCaT	IC₅₀	0.7 μM Compound: 2, Anthralin	Antiproliferative activity against human HaCaT cells assessed as dispersed cells after 48 hrs by phase-contrast microscopic analysis Antiproliferative activity against human HaCaT cells assessed as dispersed cells after 48 hrs by phase-contrast microscopic analysis	[PMID: 20850910]
HaCaT	IC₅₀	0.7 μM Compound: 3	Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy	[PMID: 22845014]
HaCaT	IC₅₀	0.7 μM Compound: 5	Antihyperproliferative activity against human HaCaT cells assessed as inhibition of cell growth after 48 hrs by phase contrast microscopy Antihyperproliferative activity against human HaCaT cells assessed as inhibition of cell growth after 48 hrs by phase contrast microscopy	[PMID: 24964246]
HaCaT	IC₅₀	0.7 μM Compound: Anthralin	Antihyperproliferative activity against human HaCaT cells after 48 hrs by MTT assay Antihyperproliferative activity against human HaCaT cells after 48 hrs by MTT assay	[PMID: 28410493]
HaCaT	IC₅₀	0.7 μM Compound: 1	Concentration required to inhibit 50% growth of HaCaT cells Concentration required to inhibit 50% growth of HaCaT cells	[PMID: 11262091]
HaCaT	IC₅₀	0.7 μM Compound: 1	In vitro for antiproliferate activity against HaCaT cells In vitro for antiproliferate activity against HaCaT cells	[PMID: 9873705]
HaCaT	IC₅₀	0.7 μM Compound: 1; DTR; dithranol	Antiproliferative activity against human HaCaT cells Antiproliferative activity against human HaCaT cells	[PMID: 26515039]
HaCaT	IC₅₀	0.7 μM Compound: anthralin	Antiproliferative activity against human HaCaT cells Antiproliferative activity against human HaCaT cells	[PMID: 10395495]
HaCaT	IC₅₀	0.7 μM Compound: Anthralin	Antiproliferative activity against human HaCaT cells Antiproliferative activity against human HaCaT cells	[PMID: 10479319]
HaCaT	IC₅₀	0.7 μM Compound: Anthralin	Antiproliferative activity against growth of HaCaT cell was determined Antiproliferative activity against growth of HaCaT cell was determined	[PMID: 11140730]
HaCaT	IC₅₀	0.945 μM Compound: 1; DTR; dithranol	Antiproliferative activity against human HaCaT cells after 24 hrs by MTT assay Antiproliferative activity against human HaCaT cells after 24 hrs by MTT assay	[PMID: 26515039]
HaCaT	IC₅₀	2.9 μM Compound: anthralin	Antiproliferative activity against human HaCaT cells assessed as [3H]thymidine incorporation after 24 hrs Antiproliferative activity against human HaCaT cells assessed as [3H]thymidine incorporation after 24 hrs	[PMID: 15387642]
HaCaT	IC₅₀	3.52 μM Compound: Anthralin	Antiproliferative activity against human HaCaT cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HaCaT cells incubated for 48 hrs by MTT assay	[PMID: 39151117]
HEK293	GI₅₀	0.5 μM Compound: 14	Growth inhibition of human NHEK cells after 72 hrs by neutral red uptake assay Growth inhibition of human NHEK cells after 72 hrs by neutral red uptake assay	[PMID: 22944332]
PMNL	IC₅₀	37 μM Compound: anthralin	Inhibition of LTB4 biosynthesis in A-23187-stimulated bovine PMNL cells Inhibition of LTB4 biosynthesis in A-23187-stimulated bovine PMNL cells	[PMID: 10395494]
THP-1	GI₅₀	54 μM Compound: 14	Growth inhibition of human THP1 cells after 72 hrs by Cell Titer 96 aqueous one solution assay Growth inhibition of human THP1 cells after 72 hrs by Cell Titer 96 aqueous one solution assay	[PMID: 22944332]
U-937	GI₅₀	5 μM Compound: 14	Growth inhibition of human U937 cells after 72 hrs by Cell Titer 96 aqueous one solution assay Growth inhibition of human U937 cells after 72 hrs by Cell Titer 96 aqueous one solution assay	[PMID: 22944332]

In Vitro

Dithranol (1.1 μM) inhibits replication in T98G cells by 50%^[2].
? Dithranol (0.1-0.5 μg/mL; 2-4 hours) increases the mRNA production of interleukin-10 receptors in a concentration dependent manner in HaCaT cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[3]

Cell Line:

HaCaT cells
Concentration:

0.1 μg/mL, 0.25 μg/mL, 0.5 μg/mL
Incubation Time:

2 hours, 4 hours
Result:

Increased the mRNA production of interleukin-10 receptors in HaCaT cells.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1143-38-0
Appearance Solid
Molecular Weight 226.23
Formula C₁₄H₁₀O₃
Color Yellow to orange
SMILES

O=C1C2=C(C=CC=C2O)CC3=CC=CC(O)=C13
Synonyms

Anthralin
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 20 mg/mL (88.41 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.4203 mL

22.1014 mL

44.2028 mL

5 mM

0.8841 mL

4.4203 mL

8.8406 mL

10 mM

0.4420 mL

2.2101 mL

4.4203 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 1 mg/mL (4.42 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1 mg/mL (4.42 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1 mg/mL (4.42 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. L Kemény , et al. Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol. 1990;3(1):1-20. [Content Brief]

[2]. J M Clark, et al. Inhibition of DNA replication and repair by anthralin or danthron in cultured human cells. J Invest Dermatol. 1982 Jul;79(1):18-22. [Content Brief]

[3]. A Farkas, et al. Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line HaCaT. Inflamm Res. 2001 Jan;50(1):44-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.4203 mL	22.1014 mL	44.2028 mL	110.5070 mL
	5 mM	0.8841 mL	4.4203 mL	8.8406 mL	22.1014 mL
	10 mM	0.4420 mL	2.2101 mL	4.4203 mL	11.0507 mL
	15 mM	0.2947 mL	1.4734 mL	2.9469 mL	7.3671 mL
	20 mM	0.2210 mL	1.1051 mL	2.2101 mL	5.5254 mL
	25 mM	0.1768 mL	0.8841 mL	1.7681 mL	4.4203 mL
	30 mM	0.1473 mL	0.7367 mL	1.4734 mL	3.6836 mL
	40 mM	0.1105 mL	0.5525 mL	1.1051 mL	2.7627 mL
	50 mM	0.0884 mL	0.4420 mL	0.8841 mL	2.2101 mL
	60 mM	0.0737 mL	0.3684 mL	0.7367 mL	1.8418 mL
	80 mM	0.0553 mL	0.2763 mL	0.5525 mL	1.3813 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Dithranol

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Human Metabolite Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Drug Fragment Library

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Dithranol

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Human Metabolite Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Drug Fragment Library

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Dithranol Related Classifications

HY-B0738 Related Classifications